No results found for "".

Commentary & Deal Flow

Related Issuers

PX TALK: Almirall E250m 5NC2 sr notes 2.25-2.50%

HYC US Market: Commentary - M&AHYC European Market: Commentary - M&AHYC European Market: Deal Flow - General

Almirall SA EUR250m 144A/Reg S sr notes due 2026 (5y). NC2 (50%,25%,par). Ba3/BB- (stable/stable). Via BNP/JPM (B&D) jt glocos/BBVA/BofA/Caixa/Santander jt books. No reg rights. List lux. NY law. IPT: mid 2s.

Px talk: 2.25%-2.50%.

Did investor call at 11am UKT Mon (virtual 1x1s Mon-Weds). Books close at 12pm UKT today. Pricing today UK afternoon. UOP: along with EUR5m cash on hand, to repay its EUR250m 0.25% cvt notes due 12/14/21. Biz: Almirall is a publicly listed pharmaceutical company that researches, develops, produces and markets a fairly diversified portfolio of in-house developed drugs and in-licensed drugs in therapeutic areas including dermatology, respiratory, gastrointestinal and pain relief. HQ: Barcelona, Spain.